OVERVIEW

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

More>>
  • Aug 28, 2018

    GAITHERSBURG, Md. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13 th Annual Biotech Conference in September. Conference details are as follows: B....More>>

  • Aug 08, 2018

    Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call Today at 4:30 pm ET GAITHERSBURG, Md. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter and six ...More>>

  • Aug 01, 2018

    GAITHERSBURG, Md. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August 8, 2018 . Conference call details are as follows: Date: August...More>>

Stock Quote